| SOURCES |
|
|
|
| sources/clingen-summary-2026-05-09 |
ClinGen 2026-05-09 Curation Activity Summary: 419 cardiovascular gene-disease curations across 258 genes; 7-tier validity framework; highlights disputed/refuting BrS/HCM/ARVC genes; SCN5A broad designation; PAH definitive genes |
clingen, gene-disease-validity, hereditary-cardiovascular-disease, dosage-sensitivity, clinical-actionability |
2026-05-09 |
| sources/hatw-jacc-advances-2025 |
Meyers 2025 JACC:Advances: first quantitative HATW definition — T-wave magnitude (AUC/QRS amplitude) + symmetry; HATW score ≥0.7 in 2 contiguous leads → 98.4% spec, 20.7% sens in non-STEMI; T-wave amplitude alone insufficient |
hyperacute-T-waves, occlusion-MI, ECG-diagnosis, acute-coronary-syndrome, STEMI-criteria |
2026-05-03 |
| sources/conduction-disorders-jaha-2025 |
Balla 2025 JAHA Contemporary Review: CCDs in young adults — acquired (Lyme 80–90% AVB, sarcoidosis 30% unexplained AVB, Chagas RBBB+LAFB, autoimmune RA/SLE) and familial (SCN5A 76% familial CCD, LMNA 33% DCM+CCD, Fabry 6% devices, Kearns-Sayre PM, Holt-Oram/NKX2-5 CHD-related); conduction system pacing preferred; PM <50 → 3–4× risk; ESC rec ICD over PM in LMNA |
conduction-disorders, atrioventricular-block, genetics, cardiomyopathy, young-adults |
2026-05-02 |
| sources/ch-aha-2026 |
AHA 2026 Scientific Statement: CH cardiovascular implications — gene-specific mechanisms (TET2/IL-1β/NLRP3; DNMT3A/efferocytosis/HB-EGF; JAK2/thrombosis); 25% HF risk (n=56,597); TET2 2.4× HFpEF; therapy-related CH (TP53/PPM1D); CANTOS canakinumab benefit in TET2-CH; colchicine/vitamin C/metformin strategies; no proven CH-specific CVD therapy |
clonal-hematopoiesis, cardiovascular-risk, inflammation, atherosclerosis, cardio-oncology |
2026-05-02 |
| sources/membrane-potential-physrev-2021 |
Varró 2021 Physiol Rev: comprehensive review of all cardiac ion channels (INa/IKr/IKs/Ito/ICaL/IK1/If/NCX), AP phases, regional differences, EAD/DAD/reentry mechanisms, electrical remodeling in AF/HF/HCM/MI, all channelopathy genes |
cardiac-electrophysiology, ion-channels, arrhythmia-mechanisms, channelopathies, electrical-remodeling |
2026-04-30 |
| sources/cardio-oncology-vascular-metabolic-aha-2019 |
AHA 2019 Scientific Statement: vascular and metabolic perspectives in cardio-oncology — vascular toxicity mechanisms table (5-FU/platinum/taxane/bleomycin/RT), VEGF HTN mechanisms, Ottawa VTE score, LMWH vs DOAC, CHIP as shared cancer-CVD risk, ADT metabolic risk |
cardio-oncology, vascular-toxicity, cancer-associated-VTE, metabolic-complications, clonal-hematopoiesis |
2026-04-30 |
| sources/alt-medicine-hf-aha-2023 |
AHA 2023 Scientific Statement: CAM in HF — omega-3 PUFA Class 2b rec; CoQ10 uncertain; hawthorn harm in LVEF ≤35%; licorice/Vit E/grapefruit juice harm; yoga/tai chi beneficial; drug-interaction catalog |
heart-failure, complementary-alternative-medicine, drug-interactions, nutraceuticals, guidelines |
2026-04-30 |
| sources/subclinical-af-aha-2019 |
AHA 2019 Scientific Statement: SCAF prevalence (10–55% CIED; 24% ESUS); 2.4× stroke risk; dose-dependent duration threshold; progression to clinical AF; pre-ARTESiA/NOAH OAC uncertainty |
subclinical-atrial-fibrillation, atrial-fibrillation, stroke-prevention, cardiac-monitoring, anticoagulation |
2026-04-29 |
| sources/genetic-test-aha-2020 |
AHA 2020 Scientific Statement: genetic testing framework across cardiomyopathies, arrhythmic disorders (SCN5A-only for BrS; KCNQ1/KCNH2/SCN5A definitive for LQTS), HTAD (11 definitive genes), and FH (Table 4 criteria); ACMG 59/30 CVD genes; cascade testing principles; GINA limitations |
genetic-testing, cardiomyopathy, channelopathies, guideline, cascade-family-screening |
2026-04-29 |
| sources/imaging-viability-aha-2020 |
AHA 2020 Scientific Statement: state-of-art viability imaging — hibernation/stunning pathophysiology; LGE-CMR transmural extent tiers; STICH/PARR-2 viability substudy; modality comparison table |
myocardial-viability, cardiac-imaging, ischemic-cardiomyopathy, late-gadolinium-enhancement, coronary-revascularization |
2026-04-29 |
| sources/sdb-arrhythmia-aha-2022 |
AHA 2022 Scientific Statement: SDB (OSA/CSA/CSB) and cardiac arrhythmias (AF/VTA/SCD/bradyarrhythmia); VARIOSA-AF directionality; CPAP RCTs all negative; NABS/ODI screening; circadian KLF15 mechanism; stepped clinical care model |
sleep-disordered-breathing, atrial-fibrillation, ventricular-arrhythmia, obstructive-sleep-apnea, arrhythmia-management |
2026-04-29 |
| sources/BPA-AHA-2024 |
AHA 2024 Scientific Statement: BPA for CTEPD with/without PH; Class I ESC 2022; RACE/MR BPA trials; disease-level classification; lesion subtypes; complication trends; expert centre requirements |
balloon-pulmonary-angioplasty, CTEPH, pulmonary-hypertension, interventional-cardiology, pulmonary-embolism |
2026-04-28 |
| sources/incident-gene-aha-2023 |
AHA 2023 Scientific Statement: Bayesian framework for interpreting incidentally identified variants in CVD genes; ACMG-78 (42 CVD genes); pretest probability + variant pathogenicity → posttest probability; LP/P-only cascade testing; 1–8%/year reclassification; diverse populations |
incidental-variants, genetic-testing, heritable-cardiovascular-disease, variant-interpretation, precision-medicine |
2026-04-28 |
| sources/imaging-cardio-oncology-aha-2024 |
AHA 2023 Scientific Statement: multimodality cardiovascular imaging in cardio-oncology; Tables 1 & 2 by therapy type and clinical presentation |
cardio-oncology, cardiovascular-imaging, echocardiography, CMR, cancer-therapy-related-cardiac-dysfunction |
2026-04-28 |
| sources/ACS-AHA-2025 |
2025 ACC/AHA/ACEP/NAEMSP/SCAI full-revision ACS guideline; ticagrelor monotherapy Class I; Impella IIa (DanGer-SHOCK); complete revascularization; IABP/VA-ECMO no benefit |
acute-coronary-syndrome, STEMI, antiplatelet-therapy, revascularization, guidelines |
2026-04-21 |
| sources/CCS-AHA-2023 |
2023 AHA/ACC/ACCP/ASPC/NLA/PCNA guideline for Chronic Coronary Disease; beta-blocker COR 3 No Benefit without LV dysfunction; ISCHEMIA paradigm; SGLT2i/GLP-1 RA COR 1; COMPASS low-dose rivaroxaban |
chronic-coronary-disease, secondary-prevention, revascularization, antiplatelet-therapy, guidelines |
2026-04-22 |
| sources/ACHD-AHA-2025 |
2025 ACC/AHA/HRS/ISACHD/SCAI full-revision guideline for adults with congenital heart disease; Eisenmenger PAH COR 1; new Fontan liver/TOF PVR criteria |
congenital-heart-disease, guideline, tetralogy-of-fallot, Fontan-circulation, Eisenmenger-syndrome |
2026-04-21 |
| sources/STT-mechanism-ACA-2026 |
Narrative review: electrophysiological basis of primary (ischemia/electrolytes) and secondary (LBBB/LVH/pacemaker) ST-T changes; injury current mechanism; hyperkalemia ECG progression |
electrocardiography, ST-T-changes, myocardial-ischemia, cardiac-electrophysiology, electrolyte-disturbances |
2026-05-01 |
| sources/failure-stemi-criteria-lad-omi-ehjacc-2025 |
Meyers 2025 EHJAcuteCVCare: STEMI criteria miss 38% of total LAD occlusions (TIMI-0 flow) on all serial ECGs; expert and AI (PMCardio Queen of Hearts) both 100% sensitive on first ECG; DBT 97 vs 40 min without vs with STEMI criteria; equivalent infarct size |
occlusion-MI, STEMI-criteria, LAD-occlusion, ECG-diagnosis, artificial-intelligence-ECG |
2026-05-02 |
| sources/acm-hrs-2019 |
2019 HRS Expert Consensus on evaluation, risk stratification, and management of ACM |
consensus, arrhythmogenic-cardiomyopathy |
2026-04-11 |
| sources/channelopathies-jaha-2025 |
Clinical diagnosis and therapeutics for cardiac channelopathies |
channelopathies, inherited-arrhythmias |
2026-04-11 |
| sources/repolarisation-jaccep-2023 |
JACC:EP 2023 state-of-the-art review: cardiac repolarization genetics (ClinGen LQTS/SQTS), T-wave morphology by genotype, EAD/TdP mechanism, 176 QT-SNPs, PRS for LQTS, AI-ECG for concealed LQTS |
long-qt-syndrome, cardiac-repolarization, channelopathies, polygenic-risk-score, short-qt-syndrome |
2026-04-30 |
| sources/eoaf-jama-2021 |
Genetic yield of WGS in early-onset AF; 10.1% carry P/LP variants, mostly cardiomyopathy genes |
atrial-fibrillation, genetics |
2026-04-11 |
| sources/gene-therapy-arrhythmia-2025 |
Gene therapy modalities for cardiac arrhythmias (ARVC, CPVT, LQTS, biological pacemaker) |
gene-therapy, channelopathies |
2026-04-11 |
| sources/HCM-AHA-2024 |
2024 AHA/ACC guideline for HCM management |
hypertrophic-cardiomyopathy, guideline |
2026-04-11 |
| sources/HCM-VA-FCVMed-2022 |
Bench-to-bedside review of ventricular arrhythmia and SCD in HCM |
hypertrophic-cardiomyopathy, sudden-cardiac-death |
2026-04-11 |
| sources/VA-DCM-Sammani-2020 |
Meta-analysis of VA predictors in DCM (n=11,451); LGE HR 5.55 strongest predictor |
dilated-cardiomyopathy, ventricular-arrhythmias |
2026-04-12 |
| sources/VA-SCD-ESC-2022 |
2022 ESC guidelines for ventricular arrhythmias and SCD prevention |
ventricular-arrhythmia, sudden-cardiac-death, guideline |
2026-04-11 |
| sources/esc-cmp-2023 |
2023 ESC guidelines for cardiomyopathy management |
cardiomyopathy, guideline |
2026-04-11 |
| sources/AF-AHA-2023 |
2023 AHA/ACC/ACCP/HRS guideline for AF diagnosis and management |
atrial-fibrillation, guideline |
2026-04-12 |
| sources/AF-ESC-2024 |
2024 ESC guidelines for AF management; AF-CARE framework; CHA2DS2-VA |
atrial-fibrillation, guideline |
2026-04-12 |
| sources/EAST-AFNET4-NEJM-2020 |
EAST-AFNET 4 RCT: early rhythm control reduces CV death/stroke in AF (HR 0.79) |
atrial-fibrillation, rhythm-control, RCT |
2026-04-12 |
| sources/ca-af-ehj-2024 |
State-of-art review: AF catheter ablation indications, PFA technology, QOL, cognition, AF progression |
atrial-fibrillation, catheter-ablation, pulsed-field-ablation |
2026-04-12 |
| sources/MYBPC3-MYH7-JACCEP-2024 |
AF substrate and catheter ablation outcomes in MYBPC3/MYH7-mediated HCM; primary atrial myopathy independent of LA pressure |
hypertrophic-cardiomyopathy, atrial-fibrillation, catheter-ablation, genetics, atrial-myopathy |
2026-04-12 |
| sources/arrhythmia-genetics-mgenetik-2025 |
Current-state review of inherited arrhythmia genetics; ClinGen gene curation, CRDS, variant reclassification, cardiogenetic centres |
channelopathy, genetics, LQTS, sudden-cardiac-death, arrhythmia |
2026-04-12 |
| sources/eoaf-riskfactor-ehj-2026 |
Prospective AF <40 without SHD (n=122): 89% lifestyle risk factors, 11.6% P/LP variants (TTN/LMNA/PKP2), 4.1% stroke with CHA₂DS₂-VA=0 |
atrial-fibrillation, early-onset-atrial-fibrillation, genetics, lifestyle-risk-factors, catheter-ablation |
2026-04-12 |
| sources/HF-AHA-2022 |
2022 AHA/ACC/HFSA HF Guideline: 4-pillar HFrEF GDMT (SGLT2i COR 1); SGLT2i COR 2a HFpEF/HFmrEF; HFimpEF; cardiac amyloidosis pathway; genetic testing COR 2a |
heart-failure, guideline, HFpEF, SGLT2-inhibitors, cardiac-amyloidosis |
2026-04-12 |
| sources/HF-ESC-2021 |
2021 ESC HF Guidelines: 4-pillar HFrEF therapy (SGLT2i added); HFmrEF category; AF management (CASTLE-AF, rate/rhythm); DCM minimum gene panel; gene-specific outcomes (LMNA, TTN) |
heart-failure, guidelines, atrial-fibrillation, cardiomyopathy, genetic-testing |
2026-04-12 |
| sources/HF-update-ESC-2023 |
2023 ESC Focused HF Update: SGLT2i Class I for HFmrEF/HFpEF; STRONG-HF post-discharge strategy; finerenone + SGLT2i for CKD+T2DM; IV iron upgraded to Class I |
heart-failure, HFpEF, SGLT2-inhibitors, guideline, acute-heart-failure |
2026-04-12 |
| sources/Cardio-Oncology-ESC-2022 |
First ESC cardio-oncology guideline (272 recommendations): HFA-ICOS risk stratification; CTRCD grading; monitoring protocols for anthracyclines/HER2/ICI/RT; AF in cancer (TBIP algorithm); long-term survivorship |
cardio-oncology, cardiovascular-toxicity, heart-failure, atrial-fibrillation, guideline |
2026-04-12 |
| sources/Biobank-AF-JAMA-2024 |
UK Biobank WES (n=403,990): 6 pLOF genes (TTN/PKP2/CTNNA3/KDM5B/RPL3L) associated with AF; combined PRS+pLOF OR 7.08; TTNtv drives 3× cardiomyopathy risk before and after AF |
atrial-fibrillation, genetics, polygenic-risk-score, cardiomyopathy, early-onset-atrial-fibrillation |
2026-04-13 |
| sources/PHT-ESC-2022 |
2022 ESC/ERS PH Guidelines: new mPAP >20 mmHg threshold; 5-group classification; 4-strata follow-up risk model; ERA+PDE5i Class I for PAH; BPA Class I for CTEPH; exercise training Class I |
pulmonary-hypertension, pulmonary-arterial-hypertension, CTEPH, right-heart-failure, guideline |
2026-04-13 |
| sources/genetic-cmp-jcf-2018 |
2018 HFSA+ACMG joint guideline for genetic evaluation of cardiomyopathy; 9 guidelines; cascade screening intervals; gene-specific yields and ICD thresholds (LMNA Guideline 9) |
genetics, cardiomyopathy, guideline, genetic-testing, cascade-family-screening |
2026-04-15 |
| sources/genetic-eoaf-ehj-2024 |
State-of-art review: genetic testing in EOAF; 4–11% P/LP yield; TTN/LMNA/PKP2/MYBPC3 dominant genes; AF precedes cardiomyopathy in ~50% TTNtv carriers; Class IIb ACC/AHA rec ≤45 years; ~60% VUS rate |
atrial-fibrillation, early-onset-atrial-fibrillation, genetic-testing, cardiomyopathy, cascade-family-screening |
2026-04-15 |
| sources/genetic-af-dxmx-jce-2022 |
Invited review: genetic basis of AF (linkage/GWAS/single-gene); 5-criterion testing framework; 4q25 SNPs modulate ablation outcomes; GENETIC-AF trial (bucindolol vs metoprolol in ADRB1 Arg389Arg HFrEF) |
atrial-fibrillation, genetic-testing, catheter-ablation, polygenic-risk-score, dilated-cardiomyopathy |
2026-04-15 |
| sources/genetic-af-cjc-2024 |
CJC White Paper: 3-tier genetic testing framework for AF; ClinGen appraisal (only SCN5A/KCNA5/TTN definitive); ablatogenomics — largest SNP-ablation study (n=3259) negative; 3 case vignettes (PKP2/MYBPC3/LMNA) |
atrial-fibrillation, genetic-testing, early-onset-atrial-fibrillation, cardiomyopathy, polygenic-risk-score |
2026-04-15 |
| sources/genetic-yield-jama-card-2022 |
Combined cardiomyopathy + arrhythmia panel (n=4,782): 19.9% overall yield; 66% of positives have management implications; combined testing gains 10.9% diagnoses vs. disease-specific panels; 42% cascade yield |
genetic-testing, cardiomyopathy, arrhythmia, diagnostic-yield, cascade-testing |
2026-04-16 |
| sources/cardiorenal-aha-2019 |
AHA 2019 Scientific Statement: CRS 5-type classification (Acute Dialysis Quality Initiative); hemodynamic (CVP-driven, not just low CO) and non-hemodynamic (FGF-23/neurohormonal/inflammatory) pathophysiology; biomarkers (NGAL, TIMP-2×IGFBP7, ST2, galectin-3); UF trials (CARRESS-HF vs UNLOAD); RAAS/beta-blocker/MRA/ARNI evidence tables by GFR; SGLT-2i in diabetic CRS (EMPA-REG, CANVAS); ICD/CRT in CKD; HF in KT recipients; palliative care |
cardiorenal-syndrome, heart-failure, kidney-dysfunction, diuretics, chronic-kidney-disease |
2026-04-30 |
| sources/lpa-aha-2021 |
AHA 2021 Scientific Statement: Lp(a) as genetically determined causal ASCVD risk factor; KIV2 CNV mechanism; HR 1.11 per 50 nmol/L (UK Biobank n=460K); PCE risk adjustment formula; assay standardisation (nmol/L vs mg/dL); OxPL pathophysiology; CAVD; pelacarsen/ARO-LPA/SLN360 trials |
lipoprotein-a, ASCVD, genetics, cardiovascular-risk, lipid-lowering |
2026-04-30 |
| sources/osa-af-jama-2018 |
Review: OSA in AF (21–74% prevalence); dual acute/chronic arrhythmogenic mechanism; CPAP reduces AF recurrence (observational); AHI limitations; no RCT evidence |
atrial-fibrillation, obstructive-sleep-apnea, CPAP, atrial-remodeling, catheter-ablation |
2026-04-18 |
| sources/vhd-esc-2025 |
2025 ESC/EACTS VHD guidelines: TAVI expanded (asymptomatic AS, BAV, AR); atrial vs ventricular SMR distinct; TEER Class I A for ventricular SMR; transcatheter TR upgraded Class IIa A; unified SVD definitions |
valvular-heart-disease, guideline, TAVI, aortic-stenosis, mitral-regurgitation |
2026-04-18 |
| sources/lqts-pregnancy-medicina-2022 |
Review: LQTS in pregnancy; postpartum 2.7× cardiac event risk; LQT2 highest risk; beta-blockers Class I; propranolol/nadolol > metoprolol; amiodarone contraindicated |
long-qt-syndrome, pregnancy, channelopathies, beta-blockers, arrhythmia-management |
2026-04-18 |
| sources/brs-jaccep-2022 |
State-of-the-art review: BrS pathophysiology, quantified risk stratification (annual SAE rates by clinical subgroup), Brugada burden concept, QUIDAM trial, ICD vs. complications data, epicardial ablation outcomes |
brugada-syndrome, risk-stratification, channelopathies, sudden-cardiac-death, inherited-arrhythmias |
2026-04-19 |
| sources/drug-arrhythmia-aha-2020 |
AHA 2020 Scientific Statement: comprehensive catalog of drug-induced arrhythmias (7 types); TdP risk factors; repolarization reserve theory; CAST trial; 0.08%/year SCD for drug-induced BrS; IV Mg for TdP |
drug-induced-arrhythmias, torsades-de-pointes, QT-prolongation, Brugada-syndrome, arrhythmia-management |
2026-04-19 |
| sources/amiodarone-cvdrug-2020 |
Comprehensive clinical review: amiodarone mechanism (all 4 AP phases), indications (VF/VT/AF), pharmacokinetics (t½ 50–60d), multisystem toxicity monitoring, drug interactions (warfarin, sofosbuvir) |
amiodarone, antiarrhythmic-drugs, drug-toxicity, ventricular-arrhythmias, atrial-fibrillation |
2026-04-19 |
| sources/HT-AHA-2025 |
2025 AHA/ACC multi-society hypertension guideline: PREVENT replaces PCEs; SPC for Stage 2; RDN COR 2b; primary aldosteronism screening in resistant HT; dementia prevention COR 1 |
hypertension, guidelines, blood-pressure-management, cardiovascular-risk, PREVENT-score |
2026-04-20 |
| sources/TTN-CVResearch-2022 |
Invited review: titin molecular biology — isoform switch (N2B/N2BA/RBM20), PTMs (acetylation/oxidation/phosphorylation), PQC, TTNtv-DCM triple pathomechanism; failed clinical trials (RELAX/VITALITY/SOCRATES) |
titin, dilated-cardiomyopathy, heart-failure, sarcomere, post-translational-modifications |
2026-04-19 |
| sources/atrial-cmp-esc-2025 |
ESC/HFA 2025 consensus: AtCM diagnostic framework (P-wave score 0–4 + LAVi >40 ml/m²/LASr <23%); atrial failure as end-stage; BMP10/mid-regional proANP biomarkers; NLRP3 inflammasome and epicardial adipose tissue targets |
atrial-cardiomyopathy, atrial-fibrillation, heart-failure, atrial-fibrosis, electrocardiography |
2026-05-01 |
| sources/csp-ehra-2023 |
2023 EHRA consensus on CSP implantation: HBP and LBBAP technique, capture confirmation criteria, complications, device configuration; endorsed by APHRS/CHRS/LAHRS |
conduction-system-pacing, his-bundle-pacing, left-bundle-area-pacing, cardiac-pacing, cardiac-resynchronization-therapy |
2026-04-19 |
| sources/csp-jaccep-2023 |
JACC:EP 2023 state-of-the-art review: CSP hemodynamics (vs RVP/BVP), ventricular synchrony (UHF-ECG), LBB capture criteria, HOT/LOT-CRT, 7 published RCTs, ongoing PROTECT-HF/Left vs Left |
conduction-system-pacing, his-bundle-pacing, left-bundle-area-pacing, cardiac-resynchronization-therapy, heart-failure |
2026-04-19 |
| sources/fabry-ehj-2024 |
EHJ 2024 state-of-the-art review: cardiologist's role in AFD; cardiac HCM genocopy; HFpEF (40%); ERT/migalastat/gene therapy; amiodarone contraindicated; CMR 4-stage model; AI diagnostics |
fabry-disease, hypertrophic-cardiomyopathy, lysosomal-storage-disorders, cardiomyopathy, enzyme-replacement-therapy |
2026-04-19 |
| sources/fabry-pcvd-2025 |
PCVD 2025 systematic review: Fabry cardiomyopathy mechanisms (TLR4/NF-κB, TGF-β, impaired autophagy); ERT paradox (LGE augmented by ERT, meta-analysis n=11); animal model failure; female AFD (mean death 55.4y); miR-17/fatigue |
fabry-disease, cardiomyopathy, enzyme-replacement-therapy, lysosomal-storage-disorders, fibrosis |
2026-04-19 |
| sources/rhc-hf-ehj-2025 |
EHJ 2025 state-of-the-art review: RHC across HF spectrum; PAWP zone of uncertainty (12–18 mmHg); normal PAWP upper limit 13 mmHg; haemodynamic thresholds for acute/chronic HF, cardiogenic shock (SCAI), LVAD, HTX |
right-heart-catheterization, pulmonary-hypertension, heart-failure, cardiogenic-shock, advanced-heart-failure |
2026-04-19 |
| sources/echo-hfpef-ase-2025 |
ASE 2025 guideline update: LV diastolic function assessment; LARS as primary LAP parameter; new 2-step diastolic dysfunction definition; revised LAP algorithm (LAVi demoted); stepwise HFpEF diagnosis algorithm; diastolic exercise echo; special populations |
echocardiography, diastolic-function, HFpEF, heart-failure, left-atrial-strain |
2026-04-19 |
| sources/VHD-AHA-2020 |
2020 ACC/AHA VHD guideline: A–D staging system; age-based TAVI vs SAVR selection; COAPT criteria for secondary MR TEER; prosthetic valve antithrombotic (INR 2.5/3.0; DOACs Class III:Harm); SVD surveillance schedule |
valvular-heart-disease, guideline, aortic-stenosis, prosthetic-valves, TAVI |
2026-04-19 |
| sources/hemodynamics-circ-2012 |
Circulation 2012 review: invasive hemodynamic catheterization principles; Gorlin/Hakki equations; AS/MS gradient measurement pitfalls; constrictive vs restrictive differential; HCM provocative maneuvers |
hemodynamics, cardiac-catheterization, valvular-heart-disease, aortic-stenosis, pulmonary-hypertension |
2026-04-20 |
| sources/lipid-aha-2026 |
2026 ACC/AHA Dyslipidemia Guideline: PREVENT equations replace PCE; LDL-C/non-HDL-C goals reinstated; universal Lp(a) measurement COR 1; CAC-guided treatment tiers; bempedoic acid/inclisiran/olezarsen incorporated |
dyslipidemia, guidelines, primary-prevention, ldl-c, ASCVD |
2026-04-20 |
| sources/lipid-esc-2025 |
2025 ESC/EAS Focused Update: SCORE2/SCORE2-OP replace SCORE; bempedoic acid COR I B for statin-intolerant; evinacumab COR IIa B for HoFH ≥5 y; ACS combination initiation; Lp(a) >105 nmol/L risk-enhancing COR IIa B; volanesorsen for FCS (EMA); statins for HIV/cancer |
dyslipidemia, guidelines, ldl-c, ASCVD, ESC |
2026-04-20 |
| sources/acute-pe-aha-2026 |
2026 AHA/ACC multi-society PE guideline; introduces 5-category AHA/ACC Acute PE Clinical Categories (A–E); PERT COR 1; DOACs over VKAs; LMWH over UFH; advanced therapy by category; CTEPD surveillance |
pulmonary-embolism, venous-thromboembolism, anticoagulation, guidelines, risk-stratification |
2026-04-21 |
| sources/periop-aha-2024 |
2024 AHA/ACC multi-society guideline for Perioperative Cardiovascular Management for NCS; stepwise algorithm; RCRI/NSQIP/DASI; MINS surveillance; BP targets (MAP ≥60–65); pharmacotherapy (SGLT2i COR 1 stop, BB COR 3 no start day-of); POAF; special populations (AS, PH, HCM, AF) |
perioperative-medicine, noncardiac-surgery, cardiovascular-risk, guideline, anticoagulation |
2026-04-22 |
| sources/imaging-amyloidosis-aha-2021 |
2021 AHA 8-society consensus on multimodality imaging in cardiac amyloidosis (Part 1): evidence base + standardized protocols; scintigraphy Grade 0–3 system; SPECT mandatory addendum; PSIR LGE; ECV >0.40 |
cardiac-amyloidosis, multimodality-imaging, ATTR-amyloidosis, echocardiography, radionuclide-imaging |
2026-04-22 |
| sources/imaging-amyloidosis-2nd-aha-2021 |
2021 AHA 8-society consensus on multimodality imaging in cardiac amyloidosis (Part 2): formal diagnostic criteria (ECV >0.40, apical GLS ratio >1, PET thresholds); AUC ratings for 32 clinical scenarios; scintigraphy Rarely Appropriate in AL |
cardiac-amyloidosis, multimodality-imaging, ATTR-amyloidosis, appropriate-use-criteria, diagnostic-criteria |
2026-04-22 |
| sources/PVD-AHA-2024 |
2024 ACC/AHA multi-society guideline for lower extremity PAD; rivaroxaban+aspirin COR 1A; SET COR 1A for claudication; BEST-CLI vs BASIL-2; CLTI multispecialty care; ALI 4–6h ischaemia window; health disparities |
peripheral-artery-disease, guidelines, revascularization, CLTI, claudication |
2026-04-24 |
| sources/rv-failure-aha-2026 |
2026 AHA Scientific Statement: RV failure in PH — RV–PA coupling (Ees/Ea thresholds), adaptive vs maladaptive remodeling, multiomics biomarkers (H19/SPARCL1/CILP1/FSTL3), imaging (CMR/PET/4D flow), sotatercept RV effects |
right-ventricular-failure, pulmonary-hypertension, RV-PA-coupling, ventricular-remodeling, multiomics-biomarkers |
2026-04-22 |
| sources/hemodynamic-hf-pht-aha-2026 |
2026 AHA Scientific Statement: standardized provocative RHC protocols — SNP/milrinone vasodilator challenge (Table 1), PAH AVT (adenosine dropped, Table 2), volume challenge (PAWP ≥19 threshold), invasive exercise HFpEF criteria (Table 4), LVAD ramp/reverse ramp, remote PA monitoring |
right-heart-catheterization, heart-failure, pulmonary-hypertension, invasive-hemodynamics, HFpEF |
2026-04-22 |
| sources/diet-aha-2026 |
2026 AHA Scientific Statement: 9-feature heart-healthy dietary pattern; alcohol initiation not recommended (MR negates protection); fish oil supplement increases AF risk; ultraprocessed foods linked to CVD/T2DM/obesity; saturated→unsaturated fat lowers LDL-C; sodium↓+potassium↑ for BP |
cardiovascular-prevention, dietary-control, nutrition-guidelines, ultraprocessed-foods, primary-prevention |
2026-04-24 |
| sources/cuffless-bp-aha-2026 |
2026 AHA Scientific Statement: cuffless BP devices (PPG/tonometry/PAT/PTT) — mechanism overview, theoretical applications, validation gaps; 2025 AHA/ACC recommends against clinical use (COR 3: No Benefit); ISO 81060-7 pending |
hypertension, blood-pressure-monitoring, digital-health, wearable-technology, photoplethysmography |
2026-04-24 |
| sources/ais-aha-2026 |
2026 AHA/ASA full AIS guideline: tenecteplase COR 1A replaces alteplase; EVT expanded (ASPECTS 3–5 COR 1A; BAO 24h COR 1A); post-EVT SBP <140 mmHg COR 3:Harm; elastic stockings COR 3:Harm; DAPT 21d for minor AIS/TIA COR 1A |
acute-ischemic-stroke, endovascular-thrombectomy, thrombolysis, stroke-management, guideline |
2026-04-24 |
| sources/DCM-Lancet-2023 |
2023 Lancet Seminar: DCM causes, mechanisms, and treatment; second hit paradigm; 12 definitive genes with genotype-phenotype table; REALM-DCM failure (LMNA p38-MAPK); TRED-HF 44% relapse; gene therapy (LAMP2/CRISPR/PLN-ASO) |
dilated-cardiomyopathy, genetics, myocarditis, gene-therapy, heart-failure |
2026-04-25 |
| sources/periop-cied-aha-2024 |
2024 AHA Scientific Statement on periprocedural management of CIEDs; device-specific magnet responses (Micra no response; AVEIR response); leadless/S-ICD/EV-ICD distinctions; three-phase multidisciplinary workflow; ICD re-enablement safety imperative |
cied-management, perioperative-care, leadless-pacemaker, electromagnetic-interference, icd |
2026-04-25 |
| sources/consumer-genetictest-aha-2025 |
2025 AHA Scientific Statement on DTC genetic testing for CVD; regulatory gaps, ACCE framework, monogenic/PRS/pharmacogenomic testing, clinical algorithm for actionable DTC results, cascade testing challenges |
genetic-testing, direct-to-consumer-genetics, polygenic-risk-scores, pharmacogenomics, precision-medicine |
2026-04-25 |
| sources/cardiac-rehab-aha-2024 |
AHA/AACVPR 2024 Scientific Statement: 9 CR core components; strength training and program quality newly standalone; hybrid/virtual delivery; LVEF ≤35% HF qualifying indication; LDL-C <70/<55, BP <130/80, HbA1c <7% targets; 70% enrollment goal |
cardiac-rehabilitation, secondary-prevention, exercise-training, heart-failure, cardiovascular-disease |
2026-04-25 |
| sources/competitive-sports-aha-2025 |
2025 AHA/ACC Scientific Statement on competitive sports in athletes with CVD; SDM paradigm shift; HCM/DCM/ACM no universal restriction; PKP2 ACM restricted; LQTS/CPVT sports reasonable under supervision; BrS no restriction; myocarditis 4–6 wk return; masters athlete guidance |
sports-cardiology, sudden-cardiac-death, shared-decision-making, cardiomyopathy, guidelines |
2026-04-25 |
| sources/ai-cardiooncology-aha-2025 |
2025 AHA Scientific Statement: AI for precision medicine in cardio-oncology; multi-omics biomarkers (genomics/transcriptomics/proteomics/metabolomics); AI risk models (90% discrimination); AI-ECG (ICI myocarditis, anthracycline LV dysfunction); NLP/LLM; national registry call; ethical challenges |
cardio-oncology, artificial-intelligence, precision-medicine, cardiotoxicity, multi-omics |
2026-04-25 |
| sources/AKI-HF-AHA-2024 |
2024 AHA Scientific Statement: kidney dysfunction in advanced HF; Heart-Kidney Profiles A/B/C; reversibility framework (TKPP >60 mmHg); LVAD/HTx perioperative kidney management; peritoneal dialysis preferred in LVAD; sHKTx when eGFR <45/<30; palliative care integration |
cardiorenal-syndrome, advanced-heart-failure, kidney-dysfunction, LVAD, heart-transplantation |
2026-04-25 |
| sources/BCNE-AHA-2025 |
2025 AHA Scientific Statement on BCNE: prior antibiotic exposure #1 cause; 2023 Duke-ISCVID criteria; metagenomic sequencing; 18F-FDG PET/CT; fastidious pathogen table (Coxiella/Bartonella/Whipple/M.chimaera/Fungi); empiric regimens; NBTE differential |
infective-endocarditis, blood-culture-negative-endocarditis, molecular-diagnostics, fastidious-organisms, scientific-statement |
2026-04-25 |
| sources/mitochondrial-cv-aha-2025 |
2026 AHA Scientific Statement: mtDNA variation in CVD; heteroplasmy dynamics; ~30% cardiac involvement in mitochondrial disease; HCM dominant phenotype; MELAS/MERRF/MIDD/KSS syndromes; NGS best practices; TALE/zinc-finger gene editing; cGAS-STING inflammatory pathway |
mitochondrial-genetics, cardiomyopathy, arrhythmia, genetic-testing, cardiovascular-disease |
2026-04-25 |
| sources/rnd-aha-2024 |
2024 AHA Scientific Statement: Renal denervation for hypertension; FDA approval (Spyral/Paradise Nov 2023); 22+ sham-controlled RCTs; 4–10 mmHg SBP reduction; patient selection, safety (no kidney impairment), shared decision-making |
hypertension, resistant-hypertension, renal-denervation, catheter-based-therapy, sympathetic-nervous-system |
2026-04-25 |
| sources/vhd-mechanism-aha-2024 |
2024 AHA Scientific Statement: molecular mechanisms of VHD (CAVD, BAV, MVP, RHD); no effective medical therapy; Lp(a)/LDL-C osteogenic cascade; statin paradox; CHIP in CAVD; TGF-β in MVP; molecular mimicry in RHD; ongoing trials (pelacarsen, colchicine) |
valvular-heart-disease, calcific-aortic-valve-disease, mitral-valve-prolapse, rheumatic-heart-disease, molecular-mechanisms |
2026-04-25 |
| sources/TV-Mx-AHA-2024 |
2024 AHA Scientific Statement: TV anatomy (Type I–IV leaflet nomenclature); 5-grade TR severity (massive/torrential); TRILUMINATE Pivotal RCT (win ratio 1.48, QoL benefit, no mortality gain); TriClip + EVOQUE FDA-approved; Cardioband annuloplasty; heterotopic replacement; lifetime management framework |
tricuspid-regurgitation, valvular-heart-disease, transcatheter-interventions, right-heart-failure, multimodality-imaging |
2026-04-25 |
| sources/alcohol-cv-aha-2025 |
2025 AHA Scientific Statement: alcohol-CVD relationships across all conditions; heavy/binge drinking consistently harmful; MR does not confirm cardioprotective effect; AF causal dose-response (abstinence RCT); ACM dose-duration-TTNtv interaction; hypertension dose-response |
alcohol-consumption, atrial-fibrillation, cardiomyopathy, hypertension, cardiovascular-risk |
2026-04-28 |
| sources/prepregnancy-aha-2023 |
AHA 2023 Scientific Statement: prepregnancy CVH (Life's Essential 8) as critical window to reduce APOs and intergenerational CVD; graded CVH–APO dose-response; no large RCTs; multilevel interventions; racial/ethnic disparities |
prepregnancy-cardiovascular-health, adverse-pregnancy-outcomes, maternal-health, health-disparities, lifes-essential-8 |
2026-04-28 |
| sources/ht-pregnancy-aha-2022 |
AHA 2022 Scientific Statement: HDP diagnosis, BP goals, pharmacotherapy; ACOG ≥160/110 vs international ≥140/90 threshold controversy; preeclampsia sFlt-1/VEGF pathophysiology; HF HR 2.7, ESKD RR 6.6 long-term risk; Black maternal mortality 41/100k |
hypertensive-disorders-of-pregnancy, preeclampsia, maternal-health, antihypertensive-therapy, blood-pressure-in-pregnancy |
2026-04-28 |
| sources/cv-pregnancy-aha-2020 |
AHA 2020 Scientific Statement: cardio-obstetrics team framework; modified WHO classification (only prospectively validated); PPCM/IPAC (recovery first 6 months; major events EF <30%); SCAD/MINOCA in pregnancy; cerebrovascular (RCVS/PRES/ICH/CVT); anticoagulation table; contraception eligibility |
cardio-obstetrics, cardiovascular-disease-in-pregnancy, peripartum-cardiomyopathy, maternal-health, anticoagulation-in-pregnancy |
2026-04-28 |
| sources/obesity-cv-aha-2021 |
AHA 2021 Scientific Statement: obesity and CVD — visceral/epicardial fat as CVD risk markers; CAD diagnosis in obesity (PET preferred over SPECT); obesity paradox (post-PCI/CABG/HF); HFpEF more strongly associated than HFrEF; every 5-BMI-unit → 16% SCD risk +29% AF risk; ≥10% weight loss → 6-fold freedom from AF |
obesity, cardiovascular-disease, heart-failure, atrial-fibrillation, coronary-artery-disease |
2026-04-29 |
| sources/noncoding-rna-aha-2020 |
AHA 2020 Scientific Statement: all ncRNA classes (miRNA/snoRNA/Y-RNA/tsRNA/lncRNA/circRNA/exRNA) in CVD; computational tools; inclisiran/patisiran/anti-miR clinical pipeline; exRNA as CVD biomarkers |
noncoding-RNA, microRNA, lncRNA, RNA-therapeutics, extracellular-RNA |
2026-04-29 |
| sources/HF-Precision-Medicine-AHA-2019 |
AHA 2019 Scientific Statement: six-omics precision medicine in HF (genomics, pharmacogenomics, epigenomics, proteomics, metabolomics, microbiomics); ADRB1/GRK5/GNB3 beta-blocker pharmacogenomics; GUIDE-IT futility; TMAO as 5-year mortality predictor |
precision-medicine, heart-failure, genomics, pharmacogenomics, omics |
2026-04-29 |
| sources/arrhythmia-cardio-oncology-aha-2021 |
AHA 2021 Scientific Statement: arrhythmias in cancer (AF most common; ibrutinib RR 4.69; ICI-myocarditis-driven AF; QT prolongation up to 22%; MADIT-CHIC CRT trial); anticoagulation in cancer-AF; autonomic dysfunction in cancer survivors |
arrhythmia, cardio-oncology, atrial-fibrillation, QT-prolongation, autonomic-dysfunction |
2026-04-29 |
| sources/cardio-oncology-drug-aha-2022 |
AHA 2022 Scientific Statement: drug-drug interactions in cardio-oncology — pharmacodynamic (hypertension/CTRCD/ICI myocarditis/VTE/bleeding/QT) and pharmacokinetic (CYP1A2/2C8/2C9/2C19/2D6/3A4/P-gp/UGT enzyme tables); DOAC/warfarin/tamoxifen/TKI management |
cardio-oncology, drug-drug-interactions, pharmacokinetics, cancer-therapy-toxicity, anticoagulation |
2026-04-29 |
| sources/Hormonal-Rx-AHA-2021 |
AHA 2021 Scientific Statement: CV risks of breast cancer endocrine therapy (AI pooled RR 1.19 vs tamoxifen; ribociclib+tamoxifen avoid; CDK4/6 RR 1.39) and prostate cancer ADT (GnRH antagonist HR 0.44–0.46; AR-directed RR 1.36); ABCDE algorithm; racial disparities |
cardio-oncology, breast-cancer, prostate-cancer, androgen-deprivation-therapy, cardiovascular-toxicity |
2026-04-29 |
| sources/minoca-aha-2019 |
AHA 2019 Scientific Statement: MINOCA definition (4th Universal MI Definition); traffic-light diagnostic algorithm; six causes (plaque disruption/vasospasm/MVD/embolism/SCAD/supply-demand mismatch); SWEDEHEART statins HR 0.77, ACEi/ARBs HR 0.82, DAPT no benefit; 4.7% 12-month mortality |
MINOCA, myocardial-infarction, coronary-vasospasm, SCAD, coronary-microvascular-dysfunction |
2026-04-29 |
| sources/pharmacological-provocation-europace-2025 |
EHRA 2025 multi-society consensus: SCB testing (ajmaline preferred; false-positive rates by disease; indications/contraindications; clinical scenarios); epinephrine for CPVT when EST not feasible; adenosine for SVT/WPW; acetylcholine/ergonovine for CAS (COVADIS criteria); SCN5A carriers generally not tested |
brugada-syndrome, pharmacological-provocation, sudden-cardiac-death, channelopathies, arrhythmia-diagnosis |
2026-04-30 |
| sources/PVC-ablation-jaccep-2024 |
JACC:EP 2024 state-of-the-art review: PVC catheter ablation indications (symptomatic PVCs, PVC-induced CMP, PVC-triggered VF); ECG localization rules; activation/pace mapping/ECGI; RF/cryo/ethanol/PFA/stereotactic radioablation; site-by-site strategies (RVOT, LV summit, papillary muscles, Purkinje, intramural); 84% acute success, 2.4% major complications |
premature-ventricular-complexes, catheter-ablation, ventricular-arrhythmias, electrophysiology, PVC-induced-cardiomyopathy |
2026-05-01 |
| sources/qwave-mri-jacc-imaging-2012 |
JACC:Imaging 2012 prospective validation study (n=46, 5-year serial LGE-CMR): Q-wave presence determined by infarct size not transmurality; 23% non-diagnostic ECG at 1 week → 44% at 5 years post-STEMI; 6.2% LV mass cutoff; pseudo-normalization confirmed |
myocardial-infarction, electrocardiography, late-gadolinium-enhancement, stemi, cardiac-mri |
2026-05-01 |
| sources/epi-adipose-arrhythmia-jacc-2021 |
JACC 2021 state-of-the-art review: EAT arrhythmogenesis via structural infiltration (zigzag conduction, re-entry), electrotonic coupling (Cx43, RMP depolarisation), and paracrine secretome (TNF-α/IL-1β/IL-6 → APD prolongation, connexin downregulation, fibrosis); ECG correlates: P-wave/PR/QRS/TpTe |
epicardial-adipose-tissue, arrhythmias, atrial-fibrillation, obesity, electrophysiology |
2026-05-01 |
| sources/circadian-scd-jmcc-2025 |
JMCC 2025 narrative review: extrinsic (SCN/ANS) and intrinsic (BMAL1/CLOCK) circadian regulation of cardiac ion channel expression; Kcnh2/Gja1/Scn5a/Hcn4/Pkp2/Dsc2/Dsg2 as top REGs; KLF15→KChIP2 indirect pathway; LQT2 mutations shortening Kv11.1 t½ amplify time-of-day APD swings; loss of morning SCA peak in modern populations |
circadian-rhythm, sudden-cardiac-death, cardiac-electrophysiology, ion-channels, arrhythmia-mechanisms |
2026-05-01 |
| sources/RYR2-CPVT-CircEP-2025 |
Chang 2025 Circ:ArrhythmElectrophysiol: largest CPVT RYR2 database — 964 patients, 263 variants; domain-specific age of onset (CSol 8y, pore 8y, NTD 12y); variant-specific treatment response (R420Q vs R420W); structural mapping onto cryo-EM (PDB 7UA5); markslab-cpvtdb.org web app; proposes exons 37/42 added to hotspot II |
CPVT, RYR2, ryanodine-receptor, variant-interpretation, sudden-cardiac-death |
2026-05-05 |
| sources/ACM-Genotype-Mx-JCE-2024 |
Muller 2025 JCE: genotype-specific ACM diagnosis and management — 7-gene natural history (PKP2/DSP/DSG2/DSC2/JUP/TMEM43/PLN/DES); 2010 TFC inadequate non-PKP2; gene-specific risk calculators (ARVC/DSP/PLN); PKP2-flecainide RCT pending; AAV-PKP2 Phase I/II (Rocket/LEXEO/Tenaya); exercise is gene-specific (not harmful in PLN); Padua criteria limitations; family screening 33%+33% yield |
arrhythmogenic-cardiomyopathy, genotype-phenotype, risk-stratification, gene-therapy, sudden-cardiac-death |
2026-05-05 |
| sources/scn5a-jaccep-2018 |
Wilde & Amin 2018 JACC:CEP state-of-the-art: full clinical spectrum of SCN5A — LQT3 (INaL GOF), BrS (LOF, partial cardiomyopathy), SCN5A-DCM (3 pathomechanisms; conduction defects precede DCM 15-20 y), MEPPC (R222Q), overlap syndromes (1795insD); mutation-direction-specific management |
SCN5A, channelopathies, long-qt-syndrome, brugada-syndrome, dilated-cardiomyopathy |
2026-05-05 |
| sources/modifier-genes-scd-ehj-2018 |
Schwartz 2018 review of modifier genes explaining incomplete penetrance in LQTS and AMI-VF; NOS1AP, KCNH2-K897T, iPSC-CM approach |
#modifier-genes, #long-qt-syndrome, #sudden-cardiac-death, #NOS1AP, #polygenic-risk-score |
2026-05-05 |
| sources/mybpc3-gene-2015 |
Carrier 2015 review of MYBPC3 biology: mutation landscape, founder mutations, cMyBP-C structure/phosphorylation/PTMs, and early gene therapy (exon skipping, RNA trans-splicing, AAV replacement) |
#MYBPC3, #hypertrophic-cardiomyopathy, #gene-therapy, #haploinsufficiency, #sarcomere |
2026-05-07 |
| sources/dronedarone-circ-2009 |
Patel/Yan/Kowey 2009 review: dronedarone pharmacology (IK-Ach 100x, INa 10x vs amiodarone), DAFNE/EURIDIS-ADONIS/ERATO/ANDROMEDA(terminated)/ATHENA(24.2% RRR)/DIONYSOS trials; HF contraindication |
#dronedarone, #atrial-fibrillation, #antiarrhythmic-drugs, #amiodarone, #heart-failure |
2026-05-07 |
| sources/flecainide-af-europace-2011 |
Aliot 2011 review: flecainide class 1C pharmacology (PRR mechanism, RyR2 blockade), CAST reappraisal, cardioversion efficacy (up to 95% IV; 90% > propafenone > amiodarone), pill-in-the-pocket, Danish registry safety data; industry-funded (Meda) |
#flecainide, #atrial-fibrillation, #antiarrhythmic-drugs, #proarrhythmia, #sodium-channel-blockade |
2026-05-07 |
| sources/amiodarone-thyroid-jcem-2021 |
Ylli 2021 JCEM Approach-to-Patient: Type 1 AIT (iodine-driven/methimazole) vs Type 2 AIT (destructive/prednisone) vs mixed (both); AIH management; incidence 2–24% (not dose-dependent); 23% ICU mortality in thyroid storm; ETA thyroidectomy criteria; anticoagulant interactions (warfarin/rivaroxaban/apixaban) |
#amiodarone, #thyroid-dysfunction, #thyrotoxicosis, #drug-toxicity, #antiarrhythmic-drugs |
2026-05-07 |
| sources/amiodarone-pulmonary-clin-chest-2004 |
Camus 2004 Clin Chest Med authoritative review: 6 APT patterns (infiltrative/OP/fibrosis/nodules/ARDS/subclinical); 100–500× lung tissue accumulation; DLCO key monitoring marker; high-FiO₂ surgery ARDS trigger; prednisolone 0.75–1 mg/kg ≥6–12 months; 21–33% hospitalisation mortality; recurrence ~2/3 on rechallenge |
#amiodarone, #drug-induced-lung-disease, #pulmonary-toxicity, #antiarrhythmic-drugs, #drug-toxicity |
2026-05-07 |
| sources/amiodarone-pulmonary-drugsafety-2010 |
Papiris 2010 Drug Safety review: amiodarone effect vs toxicity distinction; 3-mechanism pathophysiology (cytotoxic/immune/angiotensin); full 9-pattern taxonomy (CEP/COP/AFOP/amiodaronoma/NSIP-like/IPF-like/DIP/ARDS/DAH); cumulative incidence 4.2%/7.8%/10.6% at 1/3/5 years; 3-fold APT risk per decade >60; KL-6 NPV 92% (sensitivity 25%); CT density >70 HU absent in 27–55%; BAL cellular breakdown; surgical biopsy avoid; corticosteroid taper ≤5 mg/day; ACE-I/ARB potentially protective |
#amiodarone, #drug-induced-lung-disease, #pulmonary-toxicity, #antiarrhythmic-drugs, #drug-toxicity |
2026-05-07 |
| sources/gwas-arrhythmias-cmp-genes-2025 |
Dababneh 2025 Genes review: GWAS and PRS utility in HCM/DCM/BrS/LQTS; inverse HCM-DCM risk loci (MYBPC3/ALPK3/FHOD3); BrS oligogenic with 21 loci (HEY2/MAPRE2); NOS1AP as LQTS modifier; PRS predicts disease risk independent of rare variant status; European-ancestry predominance limits generalisability |
#polygenic-risk-score, #inherited-arrhythmias, #cardiomyopathy, #GWAS, #genetics |
2026-05-07 |
| sources/gene-editing-cv-tcm-2025 |
Abdul-Rahman 2025 TCM narrative review: CRISPR-Cas9/base editing/prime editing in ICCs; AAV mosaicism threshold >70%; risk-benefit framework (WPW — ablation superior; PRKAG2 syndrome — gene editing appropriate); disease table (HCM/Marfan/PAH/DMD/calmodulinopathy-LQTS/FH/PRKAG2); AI for target optimisation and safety |
#gene-editing, #CRISPR-Cas9, #inherited-cardiac-conditions, #gene-therapy, #precision-medicine |
2026-05-07 |
| sources/precision-lqts-tcm-2024 |
Neves/Ackerman 2024 TCM: 1,304-patient Mayo Clinic 20-year LQTS precision therapy cohort; 10–18 configurations per subtype; intentional nontherapy 18%; LCSD monotherapy 5%; IPAP/mexiletine for LQT2; propranolol>nadolol in LQT3; 0.3% mortality; >50% ICD extraction rate |
#long-qt-syndrome, #precision-medicine, #beta-blockers, #left-cardiac-sympathetic-denervation, #antiarrhythmic-drugs |
2026-05-09 |
| sources/aav-gene-therapy-arrhythmia-hr-2024 |
Mundisugih 2024 Heart Rhythm PRISMA meta-analysis: 26 preclinical studies; 22 novel targets; AAV9 92%; AF inducibility −81% (OR 0.19); VA inducibility −94% (OR 0.06); only PKP2 in clinical trial; 20% SCN5A base-editing threshold sufficient for LQT3; significant publication bias |
#gene-therapy, #AAV-vectors, #atrial-fibrillation, #ventricular-arrhythmia, #channelopathies |
2026-05-09 |
| sources/genetics-va-fcvm-2022 |
Wang/Tu 2022 Front Cardiovasc Med narrative review: 30+ gene reference table for non-structural VA; epigenetics — miR-19b multi-channel regulation, U1 snRNA/KCNH2 splicing, SCN5A H558R promoter methylation, KCNQ1OT1 imprinting, KChIP2/H3K4me3, SCN10A 3D enhancer-SCN5A promoter loop; TECRL mixed CPVT/LQTS phenotype; somatic RVOT-VT mutations (GNAI2/ADORA1/GNAS) |
#ventricular-arrhythmia, #inherited-arrhythmias, #epigenetics, #channelopathies, #genetics |
2026-05-09 |